Stock Price Quote

ASTEC LIFESCIENCES LTD.

NSE : ASTECBSE : 533138ISIN CODE : INE563J01010Industry : Pesticides & AgrochemicalsHouse : Godrej
BSE749.40100.3 (+15.45 %)
PREV CLOSE ( ) 649.10
OPEN PRICE ( ) 649.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 56332
TODAY'S LOW / HIGH ( )649.00 765.05
52 WK LOW / HIGH ( )512.35 990.88
NSE750.20101.1 (+15.58 %)
PREV CLOSE( ) 649.10
OPEN PRICE ( ) 652.35
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 750.20 (11356)
VOLUME 2015623
TODAY'S LOW / HIGH( ) 652.00 764.80
52 WK LOW / HIGH ( )513.4 990.82
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 25-01 1994
Management Info
Vishal Sharma - Chairman Burjis Godrej - Managing Director
Registered Office

Address Godrej One, 3rd Floor,Pirojshanagar, Eastern Express Highway ,Vikhroli (East),
Mumbai,
Maharashtra-400079

Phone 022-25188010

Email astecinfo@godrejastec.com

Website www.godrejastec.com

Registrars Details
Bigshare Services Pvt Ltd
Office No S6-2, 6th Floor, Pinnacle Business Park,Next to Ahura Centre, Mahakali Caves Road,Andheri (E),Mumbai
Listing : BSE, NSE

NEWS

06Feb Clarification sought from Astec Lifes
The Exchange has sought clarification from Astec Lifesciences Ltd on Feb..
01Aug Astec LifeSciences informs about disc
Astec LifeSciences has informed that the exchange has received the discl..
24Jun Astec Lifesciences informs about outco
Astec Lifesciences has informed that the Board of Directors of the Compa..
24Apr Astec Lifesciences informs about press
Astec Lifesciences has informed that it enclosed copies of the newspaper..
28Mar Astec Lifesciences raises Rs 49 crore
Astec Lifesciences has raised Rs 49 crore through the allotment of 4,900..

Financials

in Millions
QTR Dec 25 ANNUAL 25
Net Profit-157.2-1348.07
Gross Profit -157.2 -1411.17
Operating Profit 47.8900000000001-606.36
Net Sales 1247.23813.04

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

PI Industries (BSE)
peergroup  3114.60 (2.51%)
M.Cap ( in Cr)47254.13
Insecticides India (BSE)
peergroup  711.95 (3.71%)
M.Cap ( in Cr)2071.62
Sharda Cropchem (BSE)
peergroup  1100.65 (0.53%)
M.Cap ( in Cr)9930.12
NACL Industries (BSE)
peergroup  176.85 (2.64%)
M.Cap ( in Cr)4141.44
Mahamaya Lifescience (BSE)
peergroup  174.00 (2.35%)
M.Cap ( in Cr)407.25

Shareholding Pattern

PROMOTERS 71.97%
MUTUAL FUNDS/UTI 3.02%
NON-INSTITUTION 24.82%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Astec Lifesciences Ltd.

Astec Lifesciences Ltd. was incorporated in the year 1994. Its today's share price is 749.4. Its current market capitalisation stands at Rs 1669.83 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3893.75 Cr and Total Income of Rs.3868.62 Cr. The company's management includes Vishal Sharma, Ashok V Hiremath, Sunil Kataria, Ganapati Yadav, Anjali Gupte, Nandkumar Dhekne, RR Govindan, Burjis Godrej, Tejashree Pradhan.

It is listed on the BSE with a BSE Code of 533138 , NSE with an NSE Symbol of ASTEC and ISIN of INE563J01010. It's Registered office is at Godrej One, 3rd Floor,Pirojshanagar, Eastern Express Highway ,Vikhroli (East)Mumbai-400079, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, PM Kathariya & Co, Shah & Kathariya

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.